Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
17.04
+0.18 (1.07%)
At close: May 13, 2026, 4:00 PM EDT
17.95
+0.91 (5.31%)
After-hours: May 13, 2026, 7:58 PM EDT
Viridian Therapeutics Employees
Viridian Therapeutics had 252 employees as of December 31, 2025. The number of employees increased by 109 or 76.22% compared to the previous year.
Employees
252
Change (1Y)
109
Growth (1Y)
76.22%
Revenue / Employee
$281,421
Profits / Employee
-$1,203,440
Market Cap
1.76B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 252 | 109 | 76.22% | 252 | 0 |
| Dec 31, 2024 | 143 | 49 | 52.13% | 143 | 0 |
| Dec 31, 2023 | 94 | 8 | 9.30% | 94 | 0 |
| Dec 31, 2022 | 86 | 36 | 72.00% | 86 | 0 |
| Dec 31, 2021 | 50 | 23 | 85.19% | 50 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Recursion Pharmaceuticals | 600 |
| Agios Pharmaceuticals | 540 |
| Vericel | 398 |
| Nuvation Bio | 307 |
| Harmony Biosciences Holdings | 293 |
| Zymeworks | 264 |
| Innoviva | 159 |
| Rapport Therapeutics | 84 |
VRDN News
- 11 hours ago - Viridian Therapeutics price target lowered to $39 from $48 at Stifel - TheFly
- 6 days ago - Viridian Therapeutics 7.353M share Spot Secondary priced at $17.00 - TheFly
- 6 days ago - Viridian Therapeutics price target raised to $34 from $30 at RBC Capital - TheFly
- 7 days ago - Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million - Business Wire
- 8 days ago - Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock - Business Wire
- 8 days ago - Viridian Therapeutics Transcript: Study result - Transcripts
- 8 days ago - Viridian announces REVEAL-2 phase 3 study met primary endpoint - TheFly
- 8 days ago - Viridian Therapeutics reports Q1 EPS (90c), consensus ($1.09) - TheFly